The cancer therapeutics market size is expected to reach US$ 5,31,538.02 million by 2031 from US$ 2,30,423.56 million in 2024. The market is estimated to record a CAGR of 12.8% from 2025 to 2031.
Executive Summary and Global Market Analysis
The global cancer therapeutics market is currently undergoing significant expansion, primarily fueled by the increasing incidence rates of both breast and lung cancer, along with considerable investments directed towards oncology research. Cancer therapeutics encompass a comprehensive spectrum of treatments aimed at effectively managing or ultimately curing various forms of cancer. Prominent therapeutic modalities frequently employed include chemotherapy, radiation, immunotherapy, targeted therapy, hormone therapy, surgical interventions, and stem cell therapy. The fundamental objective of these diverse strategies is to either eradicate or gain control over cancerous cell proliferation, alleviate associated symptoms, and ultimately enhance the patient's overall quality of life and improve survival outcomes. Treatment protocols often necessitate a judicious combination of multiple therapies, meticulously tailored to the specific type and stage of cancer, as well as considering the patient's general health status, to optimize therapeutic efficacy.
Download our Sample PDF Report
@ https://www.businessmarketinsights.com/sample/BMIRE00031299
Cancer Therapeutics Market Segmentation Analysis
The cancer therapeutics market is critically analyzed across three distinct segments: therapy type, indication, and distribution channel.
By therapy type, the market is segmented into chemotherapy, targeted therapy, radiation therapy, hormone therapy, and other therapeutic approaches. Chemotherapy secured the predominant market share in 2024.
Concerning indications, the market encompasses blood cancer, lung cancer, breast cancer, colorectal cancer, prostate cancer, stomach cancer, cervical cancer, liver and intrahepatic bile duct cancer, thyroid cancer, and other specific indications. Lung cancer accounted for the largest proportion of the market in 2024.
Regarding the distribution channel, the market components include hospital pharmacies, retail pharmacies, and online stores. Hospital pharmacies maintained the largest share of the market throughout 2024.
Cancer Therapeutics Market Drivers and Opportunities
According to data from the World Health Organization, various forms of cancer are responsible for approximately 1 in every 6 deaths globally. In 2022, there were an estimated 20 million new cancer diagnoses recorded, alongside 9.7 million cancer-related deaths. This substantial disease burden is projected to escalate by approximately 77% by the year 2050, a trend that will impose considerable strain on global healthcare systems and communities worldwide. The American Cancer Society reports that a notable 5–10% of all cancers are inherited through parental lineage. A significant number of genes associated with hereditary cancer predisposition have been successfully identified. For example, specific mutations in hereditary cancer susceptibility genes such as BRCA1 and BRCA2 demonstrably elevate the risk of developing various cancers, including breast, ovarian, and prostate cancer. Breast cancer is globally recognized as the most prevalent cancer affecting women, with its incidence continuously increasing due to contributing factors such as environmental exposure, genetic susceptibility, hormonal imbalances, and evolving lifestyle choices. Furthermore, breast cancer consistently remains one of the most frequently diagnosed cancers within the U.S.
Cancer Therapeutics Market Size and Share Analysis
Based on therapy type, the cancer therapeutics market is delineated into chemotherapy, targeted therapy, radiation therapy, hormone therapy, and other therapy types. The chemotherapy segment maintained the dominant market position in 2024. Chemotherapy agents, through their inherent cytotoxic action, are highly effective in halting or significantly slowing the proliferation of cancer cells. These potent drugs are systematically delivered via the bloodstream, thereby targeting and disrupting cancer cell growth throughout the entire body. According to estimates from the National Institutes of Health, approximately 650,000 cancer patients in the US undergo chemotherapy treatment annually within specialized oncology clinics.
Regarding indications, the market is broadly segmented into blood cancer, lung cancer, breast cancer, colorectal cancer, prostate cancer, stomach cancer, cervical cancer, liver and intrahepatic bile duct cancer, thyroid cancer, and other specified indications. The lung cancer segment commanded the most substantial share of the market in 2024.
About Us:
Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Defense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications